Oric Pharmaceuticals (ORIC) to Release Earnings on Monday

Key Points

• Oric Pharmaceuticals will report Q1 2026 results before the market opens on Monday, May 4; analysts expect EPS of ($0.31) and the company will host a conference call on Tuesday, May 5 at 4:00 PM ET.
• Analysts forecast about –$1 EPS for the current fiscal year and –$2 EPS next year; the stock trades near $10.24 with a market cap of $1.03 billion and carries an average analyst rating of “Moderate Buy” with a $19.90 average price target.
• CFO Dominic Piscitelli sold 52,000 shares on Feb. 24 at an average price of $13.51, cutting his stake by roughly 43%.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) is expected to release its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect Oric Pharmaceuticals to post earnings of ($0.31) per share for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:00 PM ET.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.04. On average, analysts expect Oric Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oric Pharmaceuticals Price Performance

ORIC stock opened at $10.24 on Monday. The company's 50-day simple moving average is $11.32 and its 200-day simple moving average is $11.13. Oric Pharmaceuticals has a 52-week low of $4.52 and a 52-week high of $14.93. The firm has a market cap of $1.03 billion, a P/E ratio of -6.74 and a beta of 1.36.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ORIC. HC Wainwright reissued a "buy" rating and set a $25.00 target price on shares of Oric Pharmaceuticals in a research note on Thursday, April 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, April 21st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Oric Pharmaceuticals in a research report on Monday, March 9th. Wall Street Zen upgraded Oric Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. Finally, Wedbush decreased their target price on Oric Pharmaceuticals from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 1st. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $19.90.

Insiders Place Their Bets

In related news, CFO Dominic Piscitelli sold 52,000 shares of the firm's stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total value of $702,520.00. Following the transaction, the chief financial officer directly owned 68,148 shares of the company's stock, valued at approximately $920,679.48. This trade represents a 43.28% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.55% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Federation des caisses Desjardins du Quebec lifted its holdings in Oric Pharmaceuticals by 100.0% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company's stock valued at $33,000 after purchasing an additional 2,000 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Oric Pharmaceuticals by 184.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company's stock valued at $37,000 after purchasing an additional 2,936 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in Oric Pharmaceuticals in the 3rd quarter valued at $60,000. CANADA LIFE ASSURANCE Co purchased a new position in Oric Pharmaceuticals in the 3rd quarter valued at $65,000. Finally, Engineers Gate Manager LP purchased a new position in Oric Pharmaceuticals in the 4th quarter valued at $85,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

Oric Pharmaceuticals Company Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.